Halozyme Therapeutics | HALO - 销售收入



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 12.53B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


销售 更改 日
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amarin USD 49.22M 451K 2025-12
Amgen USD 10.1B 1.48B 2026-06
Baxter International USD 2.96B 260M 2026-06
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cytokinetics USD 28.6M 9.25M 2026-06
DBV Technologies USD 645K 2.13M 2025-12
Eli Lilly USD 22.97B 3.17B 2026-06
Halozyme Therapeutics USD 481M 104M 2026-06
Intrexon USD 717K 511K 2024-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
MannKind USD 109.37M 19.17M 2026-06
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Pfizer USD 15.03B 530M 2026-06
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
United Therapeutics USD 783.3M 1.8M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12